http://goo.gl/2rsQAN
Ofev is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue and these capsules will be available to patients within 10 days, the company said.
These twice daily oral capsules have been granted fast track, priority review, orphan product and breakthrough designations by the FDA.
IPF is a condition in which the lungs become progressively scarred over time.This fatal lung disease affects as many as 132,000 people in the US.
Most people with IPF only live three to five years after diagnosis. The disease affects men over the age of 65.